Group 1 - The Hong Kong stock market has shown positive performance with notable gains in technology-related companies such as Alibaba, Kuaishou, and SMIC, leading to increased expectations for the A-share market post-holiday [1] - 20 companies have announced share reduction plans, with 9 of them being new reduction plans, including Zhangjiang Hi-Tech, Zhejiang Wenlian, RunDa Medical, and Suotong Development [2] - Zhangjiang Hi-Tech plans to reduce its shares by up to 15,486,895 shares, not exceeding 1% of the total shares, within three months after the announcement [2] Group 2 - Lin'an Xinjing intends to reduce up to 23,746,800 shares, which is 1.60% of the total share capital, with specific limits for different trading methods [4] - RunDa Medical's shareholders, Zhu Wenyi and Liu Hui, plan to reduce their holdings by up to 10,540,000 shares and 7,460,000 shares respectively, representing 1.75% and 1.24% of the total shares [10] - Three companies have issued delisting risk warnings, including ST Dongshi, ST Suwu, and ST Zhengping, indicating potential risks of stock delisting due to low share prices [12] Group 3 - Eight companies have reported abnormal stock trading fluctuations, including Shida Shenghua, Pinming Technology, and Fengshan Group, which have issued announcements regarding these trading anomalies [12]

Key Points - Fengshan Group clarified that its sales do not involve solid-state battery electrolyte materials [1] - Zhiwei Co., Ltd. plans to invest approximately 1.5 billion yuan in the construction of high-end cast steel pump and valve components manufacturing project [1] - Tianyong Intelligent won a bid for a 58.8 million yuan DHE high-efficiency platform production line engine assembly line project [1] - Hanwei Technology intends to sell 65% of its stake in Hanwei Zhiyuan [1] - Huaxin Environmental plans to repurchase shares worth between 40 million to 80 million yuan [1] - Xin Nuo Wei is planning to issue E-shares and list on the Hong Kong Stock Exchange [1] - Shareholders of Run Da Medical, Zhu Wenyi and Liu Hui, plan to reduce their holdings by no more than 2.99% [1] - Feng Assistant intends to raise no more than 984 million yuan through a private placement to actual controllers [1] - Jiaotong Sino's chairman Li Wei has been placed under detention [1] Investment Projects - Nong Shang Environment's subsidiary plans to invest in the construction of intelligent computing center infrastructure [1] - Sai En Si (Fujian Longli Chemical) plans to invest no more than 300 million yuan in the expansion of the selection agent project [1] - Bin Hua Co. intends to invest 1.421 billion yuan in the construction of an integrated source network load storage project [1] Contracts and Acquisitions - Zhong Wu Drone signed a major contract worth 615 million yuan [1] - Xin Nuo Wei plans to acquire a 29% stake in Ju Shi Bio [1] - Huaheng Biological submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [1] - Kete Power plans to issue shares overseas (H-shares) and apply for listing on the Hong Kong Stock Exchange [1]

Core Viewpoint - The company, Fengshan Group, clarifies that its main business remains focused on the production, research, and sales of raw medicines and formulations, despite media reports linking it to the "solid-state battery" concept [1] Business Operations - The company primarily sells lithium-ion electrolytes, with sodium-ion electrolytes making up a very small portion of sales, accounting for only 0.01% of the consolidated revenue by mid-2025 [1] - The collaboration with Tsinghua University, led by Professor Zhang Qiang, is at an early research and development stage, with a small contract amount and a long project timeline extending to December 31, 2028 [1] Research and Development - The research project commissioned by the company is not the same as the significant research results recently published by Professor Zhang's team [1] - There is considerable uncertainty regarding the future research outcomes and their commercialization [1]

Core Viewpoint - Fengshan Group (603810.SH) clarifies that its main business remains focused on the production, research, and sales of raw medicines and formulations, despite media reports linking the company to the "solid-state battery" concept [1] Business Operations - The company emphasizes that its main operations have not changed, and its subsidiary Fengshan Quannuo primarily sells lithium-ion electrolytes, with sodium-ion electrolytes accounting for a relatively small proportion of sales [1] - As of the first half of 2025, sodium-ion electrolyte sales are projected to represent only 0.01% of the company's consolidated revenue [1] Research and Development - The recent important research results published by Professor Zhang Qiang's team from Tsinghua University are not related to the research and development project commissioned by the company [1] - The collaboration with Tsinghua University is still in the preliminary research and development phase, with a small contract amount, and the technical development project is expected to last until December 31, 2028, indicating significant uncertainty regarding future research outcomes and commercialization [1]

Core Viewpoint - Fengshan Group (603810.SH) clarifies that its main business remains focused on the production, research, and sales of raw medicines and formulations, despite media reports linking the company to the "solid-state battery" concept [1] Business Operations - The company’s main business has not changed, and its subsidiary Fengshan Quannuo primarily sells lithium-ion electrolytes, with sodium-ion electrolytes accounting for a relatively small proportion of sales [1] - As of the first half of 2025, sodium-ion electrolyte sales are expected to represent only 0.01% of the company’s consolidated revenue [1] Research and Development - The important research results published by Professor Zhang Qiang's team from Tsinghua University are not related to the research and development project commissioned by the company [1] - The collaboration with Tsinghua University is still in the preliminary research and development phase, with a small contract amount, and the technical development project is scheduled to last until December 31, 2028, indicating significant uncertainty regarding future research outcomes and commercialization [1]

Core Viewpoint - The company, Fengshan Group (603810.SH), clarifies that its main business remains focused on the production, research, and sales of raw medicines and formulations, despite recent media reports linking it to the "solid-state battery" concept [1] Business Operations - The company’s main business has not changed, and its subsidiary, Fengshan Quannuo, primarily sells lithium-ion electrolytes, with sodium-ion electrolytes making up a relatively small portion of sales [1] - As of the first half of 2025, sodium-ion electrolyte sales are expected to account for only 0.01% of the company's consolidated revenue [1] Research and Development - The important research results published by Professor Zhang Qiang's team from Tsinghua University are not related to the research and development project commissioned by the company [1] - The collaboration with Tsinghua University is still in the preliminary research and development phase, with a small contract amount, and the technical development project is scheduled to last until December 31, 2028 [1] - There is significant uncertainty regarding the subsequent research outcomes and their commercialization [1]

Core Viewpoint - The company clarifies that its main business remains focused on the production, research, and sales of raw medicines and formulations, despite media reports linking it to the "solid-state battery" concept [1] Business Operations - The company's main business has not changed, and its subsidiary, Fengshan Quannuo, primarily sells lithium-ion electrolytes, with sodium-ion electrolytes making up a relatively small portion of sales [1] - As of the first half of 2025, sodium-ion electrolyte sales are expected to account for only 0.01% of the company's consolidated revenue [1] Research and Development - The important research results published by Professor Zhang Qiang's team from Tsinghua University are not related to the company's commissioned research and development project [1] - The collaboration with Tsinghua University is currently in the preliminary research and development phase, with a small contract amount, and the technology development project is scheduled to last until December 31, 2028 [1] - There is significant uncertainty regarding the subsequent research outcomes and their commercialization [1]

Core Viewpoint - The company, Fengshan Group, clarifies that its main business remains focused on the production, research, and sales of raw medicines and formulations, despite recent media speculation linking it to the "solid-state battery" concept [1] Business Operations - The company’s main business has not changed, and its subsidiary, Fengshan Quannuo, primarily sells lithium-ion electrolytes, with sodium-ion electrolytes accounting for a relatively small proportion of sales [1] - As of the first half of 2025, the sales revenue from sodium-ion electrolytes is expected to represent only 0.01% of the company's consolidated operating income [1] Research and Development - The recent important research results published by Professor Zhang Qiang's team from Tsinghua University are not related to the research and development project commissioned by the company [1] - The collaboration with Tsinghua University is still in the preliminary research and development phase, with a small contract amount, and the technical development project is scheduled to last until December 31, 2028 [1] - There is significant uncertainty regarding the subsequent research outcomes and their commercialization [1]

| 证券代码：603810 | 证券简称：丰山集团 | 公告编号：2025-065 | | --- | --- | --- | | 转债代码：113649 | 转债简称：丰山转债 | | 江苏丰山集团股份有限公司 关于股票交易异常波动暨风险提示公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： （一）生产经营情况 经公司自查，公司目前生产经营情况正常，内外部经营环境未发生重大调整， 内部生产经营秩序正常。 （二）重大事项情况 1、经公司自查，截至本公告披露日，公司不存在涉及上市公司应披露而未 披露的重大事项，包括但不限于重大资产重组、股份发行、收购、债务重组、业 务重组、资产剥离、资产注入、股份回购、股权激励、破产重整、重大业务合作、 引进战略投资者等重大事项。 2、经公司向控股股东、实际控制人问询核实，截至本公告披露日，控股股 东、实际控制人不存在涉及公司应披露而未披露的重大事项，包括但不限于重大 资产重组、股份发行、收购、债务重组、业务重组、资产剥离、资产注入、股份 回购、股权激励、破产重整、重大业 ...

Core Viewpoint - Fengshan Group (603810) clarifies that its main business remains focused on the production, research, and sales of raw medicines and formulations, despite media reports linking the company to the "solid-state battery" concept [1] Business Operations - The company’s main business has not changed, and its subsidiary Fengshan Quannuo primarily sells lithium-ion electrolytes, with sodium-ion electrolytes accounting for a relatively small proportion of sales [1] - As of the first half of 2025, sodium-ion electrolyte sales are expected to represent only 0.01% of the company’s consolidated revenue [1] Research and Development - The recent important research results published by Professor Zhang Qiang's team from Tsinghua University are not related to the research and development project commissioned by the company [1] - The collaboration with Tsinghua University is still in the preliminary research and development phase, with a small contract amount, and the technical development project is scheduled to last until December 31, 2028, indicating significant uncertainty regarding future research outcomes and commercialization [1]